<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01932450</url>
  </required_header>
  <id_info>
    <org_study_id>CZKIPLA-ADPKD-001</org_study_id>
    <nct_id>NCT01932450</nct_id>
  </id_info>
  <brief_title>Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control</brief_title>
  <acronym>RAFALE</acronym>
  <official_title>A Randomized, Open-label Study Investigating the Effect of Bilateral Renal Artery Sympathetic Denervation by Catheter-based Radiofrequency Ablation on Blood Pressure and Disease Progression in Autosomal Dominant Polycystic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mei changlin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Changzheng Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label single-center study investigates the efficacy and safety of
      bilateral renal artery sympathetic denervation by catheter-based radiofrequency ablation on
      blood pressure and disease progression control in autosomal dominant polycystic kidney
      disease(ADPKD). The total number of study subjects will be 100. All of them have diagnosed
      with ADPKD and hypertension. Patients will be randomized 1:1 (50 with radiofrequency
      ablation(RFA), 50 only with drugs). Change in average office-based measurements of systolic
      blood pressure(SBP), average 24-hour systolic blood pressure by ambulatory blood pressure
      monitoring (ABPM) , incidence of office systolic blood pressure reductions of ≥10, ≥15 and
      ≥20 mm Hg , office diastolic blood pressure (DBP), number and dosage of blood pressure
      tablets, total kidney volume (TKV), total cyst volume (TCV), pain related to cystic kidneys
      and renal function, will be assessed at 12 months of follow-up. The safety variables will be
      assessed at every visit of follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>office-based measurements of systolic blood pressure</measure>
    <time_frame>baseline and 12 months (day 360±14)</time_frame>
    <description>Between-group change in average office-based measurements of systolic blood pressure from baseline to 12 months after randomization and One-time standard bilateral renal sympathetic denervation by catheter-based radiofrequency ablation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-hour systolic blood pressure by ambulatory blood pressure monitoring (ABPM)</measure>
    <time_frame>baseline and 12 months (day 360±14)</time_frame>
    <description>Change in average 24-hour systolic blood pressure by ambulatory blood pressure monitoring (ABPM) from baseline to 12 month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of office systolic blood pressure reduction</measure>
    <time_frame>baseline and 12 months (day 360±14)</time_frame>
    <description>Incidence of office systolic blood pressure reductions of ≥10, ≥15 and ≥20 mm Hg from baseline to 12 month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>office diastolic blood pressure</measure>
    <time_frame>baseline and 12 months (day 360±14)</time_frame>
    <description>Change in office diastolic blood pressure from baseline to 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number and dosage of blood pressure tablets</measure>
    <time_frame>baseline and 12 months (day 360±14)</time_frame>
    <description>Change in number and dosage of blood pressure tablets from baseline to 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated Glomerular Filtration Rate(eGFR)</measure>
    <time_frame>baseline and 12 months (day 360±14)</time_frame>
    <description>Change in estimated Glomerular Filtration Rate(eGFR) from baseline to 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>albuminuria</measure>
    <time_frame>baseline and 12 months (day 360±14)</time_frame>
    <description>Change in albuminuria from baseline to 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total kidney volume (TKV)</measure>
    <time_frame>baseline and 12 months (day 360±14)</time_frame>
    <description>Change in total kidney volume (TKV) from baseline to 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain</measure>
    <time_frame>baseline and 12 months (day 360±14)</time_frame>
    <description>Change in pain related to cystic kidneys from baseline to 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procedure-related complications at femoral puncture site</measure>
    <time_frame>up to 1 year (after radiofrequency ablation)</time_frame>
    <description>Occurrence of procedure-related complications at femoral puncture site (hematoma, arteriovenous fistula, pseudoaneurysma).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal artery lesion</measure>
    <time_frame>up to 1 year (after radiofrequency ablation)</time_frame>
    <description>Renal artery lesion (perforation or dissection).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New renal artery stenosis</measure>
    <time_frame>up to 1 year (after radiofrequency ablation)</time_frame>
    <description>New renal artery stenosis &gt;70%, determined by MRI within 12 months of randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embolic events</measure>
    <time_frame>up to 1 year (after radiofrequency ablation)</time_frame>
    <description>Embolic events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypotension</measure>
    <time_frame>up to 1 year (after radiofrequency ablation)</time_frame>
    <description>Episodes of hypotension.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypertension.</measure>
    <time_frame>up to 1 year (after radiofrequency ablation)</time_frame>
    <description>Episodes of hypertension.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute kidney injury</measure>
    <time_frame>up to 1 year (after radiofrequency ablation)</time_frame>
    <description>Acute deterioration of renal function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total cyst volume (TCV)</measure>
    <time_frame>baseline and 12 months (day 360±14)</time_frame>
    <description>Change in total cyst volume (TCV) from baseline to 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Autosomal Dominant Polycystic Kidney Disease</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>renal sympathetic denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One-time standard bilateral renal sympathetic denervation by catheter-based radiofrequency ablation and using antihypertensive drugs which at least include an angiotensin converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antihypertensive drugs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood pressure control in ADPKD patients with hypertension only using antihypertensive drugs which at least include an angiotensin converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>renal sympathetic denervation</intervention_name>
    <description>One-time standard Catheter-based renal sympathetic denervation will be performed in both renal arteries by radiofrequency ablation.</description>
    <arm_group_label>renal sympathetic denervation</arm_group_label>
    <other_name>Percutaneous radiofrequency ablation of renal nerves</other_name>
    <other_name>Transcatheter renal denervation</other_name>
    <other_name>renal denervation</other_name>
    <other_name>renal ablation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antihypertensive drugs</intervention_name>
    <description>antihypertensive drugs have been used from baseline in patients, and will be modified by patient's blood pressure.</description>
    <arm_group_label>renal sympathetic denervation</arm_group_label>
    <arm_group_label>antihypertensive drugs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ADPKD.

          -  Having hypertension, defined as systolic blood pressure ≥140 mm Hg and/or diastolic
             blood pressure ≥90 mm Hg, and currently using 2 antihypertensive drugs and receiving a
             stable antihypertensive treatment regimen without change in dose or medication in the
             previous 30 days.

          -  Male and female patients 20 years to 60 years of age.

          -  Glomerular Filtration Rate (GFR) ≥30 ml/min/1.73 m2, estimated from serum creatinine
             using the Chronic Kidney Disease Epidemiology collaboration(CKD-EPI) equation.

          -  Have followed-up kidney and cyst volume at least 6 months in Shanghai Changzheng
             Hospital.

          -  Signed Informed Consent after being informed.

        Exclusion Criteria:

          -  Documented renal vascular disease.

          -  Congenital absence of a kidney.

          -  Systemic illness with renal involvement.

          -  Spot urine albumin-to-creatinine ratio of &gt;0.5 g/g and/or findings suggestive of
             kidney disease other than ADPKD.

          -  Exclusions specific to MRI acquisition and measurement: cardiac pacemaker, presence of
             MRI incompatible metallic clips or other material, excessive body weight, untreatable
             claustrophobia.

          -  Contraindications to the catheter-based renal denervation procedure by RFA, including
             allergy to radioiodinated contrast agents. Anatomical abnormalities of the renal
             arteries which preclude RFA: presence in either kidneys of multiple main renal
             arteries, main renal artery stenosis &gt;50%, or main renal arteries of &lt;4 mm in diameter
             or &lt;20 mm in length.

          -  Contraindications on ethical grounds.

          -  Women who are pregnant or breast feeding.

          -  Intention to become pregnant during the course of the study.

          -  Lack of safe contraception: Female subjects of childbearing potential, not using and
             not willing to continue using a medically reliable method of contraception for the
             entire study duration, such as oral, injectable, or implantable contraceptives, or
             intrauterine contraceptive devices, or who are not using any other method considered
             sufficiently reliable by the investigator in individual cases (Female subjects who are
             surgically sterilized/hysterectomized or post-menopausal for longer than 2 years are
             not considered as being of child bearing potential).

          -  Other clinically significant concomitant disease states (hepatic dysfunction,
             cardiovascular disease, metastatic cancer).

          -  Known or suspected non-compliance, drug or alcohol abuse.

          -  Inability to follow the procedures of the study, e.g. due to language problems,
             psychological disorders, dementia or confusional state of the subject.

          -  Participation in another study with investigational drug within the 30 days preceding
             and during the present study.

          -  Previous enrolment into the current study.

          -  Enrolment of the investigator, his/her family members, employees and other dependent
             persons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changlin Mei, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nephrology Department of Shanghai Changzheng Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Changlin Mei, MD</last_name>
    <phone>+86 21 81885391</phone>
    <email>chlmei1954@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yiyi Ma, Master</last_name>
    <phone>+8613661679863</phone>
    <email>dukemm@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Nephrology, Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changlin Mei, MD</last_name>
      <phone>+862181885391</phone>
      <email>chlmei1954@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Yiyi Ma, Master</last_name>
      <phone>+8613661679863</phone>
      <email>dukemm@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Changlin Mei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shengqiang Yu, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lin Li, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xueqi Wang, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chenggang Xu, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhiguo Mao, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bing Dai, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yiyi Ma, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dongping Chen, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007 Apr 14;369(9569):1287-301. Review.</citation>
    <PMID>17434405</PMID>
  </reference>
  <reference>
    <citation>Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med. 2009;60:321-37. doi: 10.1146/annurev.med.60.101707.125712. Review.</citation>
    <PMID>18947299</PMID>
  </reference>
  <reference>
    <citation>Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008 Oct 2;359(14):1477-85. doi: 10.1056/NEJMcp0804458. Review.</citation>
    <PMID>18832246</PMID>
  </reference>
  <reference>
    <citation>Chang MY, Ong AC. Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and treatment. Nephron Physiol. 2008;108(1):p1-7. Epub 2007 Dec 13. Review.</citation>
    <PMID>18075279</PMID>
  </reference>
  <reference>
    <citation>Neumann J, Ligtenberg G, Klein IH, Blankestijn PJ. Pathogenesis and treatment of hypertension in polycystic kidney disease. Curr Opin Nephrol Hypertens. 2002 Sep;11(5):517-21. Review.</citation>
    <PMID>12187316</PMID>
  </reference>
  <reference>
    <citation>Chapman AB, Johnson AM, Rainguet S, Hossack K, Gabow P, Schrier RW. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1997 Aug;8(8):1292-7.</citation>
    <PMID>9259356</PMID>
  </reference>
  <reference>
    <citation>Ecder T, Schrier RW. Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects. J Am Soc Nephrol. 2001 Jan;12(1):194-200. Review.</citation>
    <PMID>11134267</PMID>
  </reference>
  <reference>
    <citation>Chapman AB, Stepniakowski K, Rahbari-Oskoui F. Hypertension in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis. 2010 Mar;17(2):153-63. doi: 10.1053/j.ackd.2010.01.001. Review.</citation>
    <PMID>20219618</PMID>
  </reference>
  <reference>
    <citation>Cerasola G, Vecchi M, Mulè G, Cottone S, Mangano MT, Andronico G, Contorno A, Parrino I, Renda F, Pavone G. Sympathetic activity and blood pressure pattern in autosomal dominant polycystic kidney disease hypertensives. Am J Nephrol. 1998;18(5):391-8.</citation>
    <PMID>9730562</PMID>
  </reference>
  <reference>
    <citation>Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol. 2001 Nov;12(11):2427-33.</citation>
    <PMID>11675419</PMID>
  </reference>
  <reference>
    <citation>Schrier RW. Hypertension and autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2011 Jun;57(6):811-3. doi: 10.1053/j.ajkd.2011.02.379.</citation>
    <PMID>21601126</PMID>
  </reference>
  <reference>
    <citation>Chapman AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Miller JP, Miskulin DC, Rahbari Oskoui F, Masoumi A, Hogan MC, Winklhofer FT, Braun W, Thompson PA, Meyers CM, Kelleher C, Schrier RW. The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol. 2010 Jan;5(1):102-9. doi: 10.2215/CJN.04310709.</citation>
    <PMID>20089507</PMID>
  </reference>
  <reference>
    <citation>Torres VE, Chapman AB, Perrone RD, Bae KT, Abebe KZ, Bost JE, Miskulin DC, Steinman TI, Braun WE, Winklhofer FT, Hogan MC, Oskoui FR, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin DR, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Meyers CM, Schrier RW; HALT PKD Study Group. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int. 2012 Mar;81(6):577-85. doi: 10.1038/ki.2011.411. Epub 2011 Dec 28.</citation>
    <PMID>22205355</PMID>
  </reference>
  <reference>
    <citation>Gattone VH 2nd, Siqueira TM Jr, Powell CR, Trambaugh CM, Lingeman JE, Shalhav AL. Contribution of renal innervation to hypertension in rat autosomal dominant polycystic kidney disease. Exp Biol Med (Maywood). 2008 Aug;233(8):952-7. doi: 10.3181/0802-RM-54. Epub 2008 May 14.</citation>
    <PMID>18480417</PMID>
  </reference>
  <reference>
    <citation>Chapuis O, Sockeel P, Pallas G, Pons F, Jancovici R. Thoracoscopic renal denervation for intractable autosomal dominant polycystic kidney disease-related pain. Am J Kidney Dis. 2004 Jan;43(1):161-3.</citation>
    <PMID>14712440</PMID>
  </reference>
  <reference>
    <citation>Valente JF, Dreyer DR, Breda MA, Bennett WM. Laparoscopic renal denervation for intractable ADPKD-related pain. Nephrol Dial Transplant. 2001 Jan;16(1):160.</citation>
    <PMID>11209012</PMID>
  </reference>
  <reference>
    <citation>Hogan MC, Norby SM. Evaluation and management of pain in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis. 2010 May;17(3):e1-e16. doi: 10.1053/j.ackd.2010.01.005. Review.</citation>
    <PMID>20439087</PMID>
  </reference>
  <reference>
    <citation>MORRISSEY DM, BROOKES VS, COOKE WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet. 1953 Feb 28;1(6757):403-8.</citation>
    <PMID>13024041</PMID>
  </reference>
  <reference>
    <citation>SMITHWICK RH, THOMPSON JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953 Aug 15;152(16):1501-4.</citation>
    <PMID>13061307</PMID>
  </reference>
  <reference>
    <citation>EVELYN KA, SINGH MM, CHAPMAN WP, PERERA GA, THALER H. Effect of thoracolumbar sympathectomy on the clinical course of primary (essential) hypertension. A ten-year study of 100 sympathectomized patients compared with individually matched, symptomatically treated control subjects. Am J Med. 1960 Feb;28:188-221.</citation>
    <PMID>13821037</PMID>
  </reference>
  <reference>
    <citation>Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009 Aug 27;361(9):932-4. doi: 10.1056/NEJMc0904179.</citation>
    <PMID>19710497</PMID>
  </reference>
  <reference>
    <citation>Schlaich MP, Hering D, Sobotka P, Krum H, Lambert GW, Lambert E, Esler MD. Effects of renal denervation on sympathetic activation, blood pressure, and glucose metabolism in patients with resistant hypertension. Front Physiol. 2012 Feb 2;3:10. doi: 10.3389/fphys.2012.00010. eCollection 2012.</citation>
    <PMID>22347190</PMID>
  </reference>
  <reference>
    <citation>Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009 Apr 11;373(9671):1275-81. doi: 10.1016/S0140-6736(09)60566-3. Epub 2009 Mar 28.</citation>
    <PMID>19332353</PMID>
  </reference>
  <reference>
    <citation>Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011 May;57(5):911-7. doi: 10.1161/HYPERTENSIONAHA.110.163014. Epub 2011 Mar 14.</citation>
    <PMID>21403086</PMID>
  </reference>
  <reference>
    <citation>Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010 Dec 4;376(9756):1903-9. doi: 10.1016/S0140-6736(10)62039-9. Epub 2010 Nov 17.</citation>
    <PMID>21093036</PMID>
  </reference>
  <reference>
    <citation>Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM, Katzen BT, Leon MB, Massaro JM, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend RR, Bakris G. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012 Sep;35(9):528-35. doi: 10.1002/clc.22008. Epub 2012 May 9.</citation>
    <PMID>22573363</PMID>
  </reference>
  <reference>
    <citation>Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, Sobotka PA, Böhm M, Cremers B, Esler MD, Schlaich MP. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012 Jul;23(7):1250-7. doi: 10.1681/ASN.2011111062. Epub 2012 May 17.</citation>
    <PMID>22595301</PMID>
  </reference>
  <reference>
    <citation>Casale P, Meyers K, Kaplan B. Follow-up for laparoscopic renal denervation and nephropexy for autosomal dominant polycystic kidney disease-related pain in pediatrics. J Endourol. 2008 May;22(5):991-3. doi: 10.1089/end.2007.0359.</citation>
    <PMID>18370613</PMID>
  </reference>
  <reference>
    <citation>Schlaich MP, Krum H, Esler MD. New therapeutic approaches to resistant hypertension. Curr Hypertens Rep. 2010 Aug;12(4):296-302. doi: 10.1007/s11906-010-0119-1. Review.</citation>
    <PMID>20509010</PMID>
  </reference>
  <reference>
    <citation>Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wüthrich RP. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010 Aug 26;363(9):820-9. doi: 10.1056/NEJMoa0907419. Epub 2010 Jun 26.</citation>
    <PMID>20581391</PMID>
  </reference>
  <reference>
    <citation>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996 Mar 1;93(5):1043-65.</citation>
    <PMID>8598068</PMID>
  </reference>
  <reference>
    <citation>Celermajer DS. Testing endothelial function using ultrasound. J Cardiovasc Pharmacol. 1998;32 Suppl 3:S29-32. Review.</citation>
    <PMID>9883744</PMID>
  </reference>
  <reference>
    <citation>Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, Lerman A, Mancia G, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Schiffrin EL, Taddei S, Webb DJ; Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005 Jan;23(1):7-17. Review.</citation>
    <PMID>15643116</PMID>
  </reference>
  <reference>
    <citation>Gemignani V, Bianchini E, Faita F, Giannarelli C, Plantinga Y, Ghiadoni L, Demi M. Ultrasound measurement of the brachial artery flow-mediated dilation without ECG gating. Ultrasound Med Biol. 2008 Mar;34(3):385-91. Epub 2007 Oct 26.</citation>
    <PMID>17964069</PMID>
  </reference>
  <reference>
    <citation>Sudano I, Flammer AJ, Périat D, Enseleit F, Hermann M, Wolfrum M, Hirt A, Kaiser P, Hurlimann D, Neidhart M, Gay S, Holzmeister J, Nussberger J, Mocharla P, Landmesser U, Haile SR, Corti R, Vanhoutte PM, Lüscher TF, Noll G, Ruschitzka F. Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation. 2010 Nov 2;122(18):1789-96. doi: 10.1161/CIRCULATIONAHA.110.956490. Epub 2010 Oct 18.</citation>
    <PMID>20956208</PMID>
  </reference>
  <reference>
    <citation>Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006 Mar 7;113(9):1213-25. Epub 2006 Feb 13.</citation>
    <PMID>16476843</PMID>
  </reference>
  <reference>
    <citation>Pannier B, Guérin A, London G, Asmar R, Safar M; REASON Study. [Combination of low-dose perindopril/indapamide versus atenolol in the hypertensive patient. Effects on systolic pressure and arterial hemodynamics. REASON Study]. Arch Mal Coeur Vaiss. 2002 Sep;95 Spec No 6:11-6. French.</citation>
    <PMID>12407781</PMID>
  </reference>
  <reference>
    <citation>Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H; European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006 Nov;27(21):2588-605. Epub 2006 Sep 25.</citation>
    <PMID>17000623</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2013</study_first_submitted>
  <study_first_submitted_qc>August 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2013</study_first_posted>
  <last_update_submitted>September 23, 2014</last_update_submitted>
  <last_update_submitted_qc>September 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Changzheng Hospital</investigator_affiliation>
    <investigator_full_name>Mei changlin</investigator_full_name>
    <investigator_title>Chief Physician, Professor, The director of Nephrology department and Internal Medicine department</investigator_title>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>radiofrequency ablation</keyword>
  <keyword>autosomal dominant polycystic kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

